The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| FHTX | -49.28% | -73.69% | -23.43% | -77% |
| S&P | +19.61% | +98.99% | +14.75% | +98% |
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $7.56M | 9.7% |
| Gross Profit | $6.66M | 9.3% |
| Gross Margin | 88.09% | -0.3% |
| Market Cap | $261.98M | -17.7% |
| Market Cap / Employee | $2.34M | 0.0% |
| Employees | 112 | -3.4% |
| Net Income | -$17.94M | 21.9% |
| EBITDA | -$20.20M | 13.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $73.82M | -46.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $17.52M | -46.2% |
| Short Term Debt | $6.18M | -26.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -27.18% | -1.3% |
| Return On Invested Capital | 80.13% | 205.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$21.02M | 17.7% |
| Operating Free Cash Flow | -$21.00M | 17.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -18.30 | -9.28 | -4.46 | -4.25 | 69.12% |
| Price to Sales | 22.84 | 11.61 | 9.76 | 12.24 | 45.27% |
| Price to Tangible Book Value | -18.30 | -9.28 | -4.46 | -4.25 | 69.12% |
| Enterprise Value to EBITDA | -15.31 | -2.40 | -1.98 | -5.93 | 165.60% |
| Total Debt | $39.07M | $37.13M | $34.85M | $23.70M | -42.08% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
